CO2019009413A2 - Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados - Google Patents
Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificadosInfo
- Publication number
- CO2019009413A2 CO2019009413A2 CONC2019/0009413A CO2019009413A CO2019009413A2 CO 2019009413 A2 CO2019009413 A2 CO 2019009413A2 CO 2019009413 A CO2019009413 A CO 2019009413A CO 2019009413 A2 CO2019009413 A2 CO 2019009413A2
- Authority
- CO
- Colombia
- Prior art keywords
- purified
- cannabinoids
- terpenes
- compositions comprise
- selected compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
En este documento se divulgan nuevas composiciones que comprenden un cannabinoide purificado y un terpeno purificado. En una realización, las composiciones comprenden uno o más cannabinoides purificados. En una realización, las composiciones comprenden uno o más cannabinoides purificados en combinación con uno o más terpenos purificados. En una realización, las composiciones comprenden proporciones no naturales. En una realización, las composiciones comprenden concentraciones no naturales. En una realización, las composiciones comprenden efectos inesperados y/o sinérgicos.
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465688P | 2017-03-01 | 2017-03-01 | |
| US201762469415P | 2017-03-09 | 2017-03-09 | |
| US201762475153P | 2017-03-22 | 2017-03-22 | |
| US201762477990P | 2017-03-28 | 2017-03-28 | |
| US201762489360P | 2017-04-24 | 2017-04-24 | |
| US201762490567P | 2017-04-26 | 2017-04-26 | |
| US201762490465P | 2017-04-26 | 2017-04-26 | |
| US201762491160P | 2017-04-27 | 2017-04-27 | |
| US201762491175P | 2017-04-27 | 2017-04-27 | |
| US201762491899P | 2017-04-28 | 2017-04-28 | |
| US201762491980P | 2017-04-28 | 2017-04-28 | |
| US201762509651P | 2017-05-22 | 2017-05-22 | |
| US201762510229P | 2017-05-23 | 2017-05-23 | |
| US201762510672P | 2017-05-24 | 2017-05-24 | |
| US201762510660P | 2017-05-24 | 2017-05-24 | |
| US201762511218P | 2017-05-25 | 2017-05-25 | |
| US15/616,874 US20170266153A1 (en) | 2015-02-27 | 2017-06-07 | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| PCT/US2018/020440 WO2018160827A1 (en) | 2017-03-01 | 2018-03-01 | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019009413A2 true CO2019009413A2 (es) | 2019-09-09 |
Family
ID=63370542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0009413A CO2019009413A2 (es) | 2017-03-01 | 2019-08-29 | Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3589129A4 (es) |
| CN (1) | CN110582206A (es) |
| AU (1) | AU2018227544A1 (es) |
| BR (1) | BR112019018088A2 (es) |
| CA (1) | CA3054690A1 (es) |
| CO (1) | CO2019009413A2 (es) |
| IL (1) | IL268929A (es) |
| MX (1) | MX2019010370A (es) |
| PE (1) | PE20200383A1 (es) |
| WO (1) | WO2018160827A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019147690A1 (en) | 2018-01-23 | 2019-08-01 | High Sierra Technologies, Inc. | Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons |
| IL266151A (en) * | 2019-04-18 | 2019-07-31 | Kanabo Res Ltd | Dilute for the cannabinoid preparations |
| CA3148236A1 (en) | 2019-07-22 | 2021-01-28 | Canopy Growth Corporation | Continuous crystallization of cannabinoids in a stirred-tank reactor |
| AU2020392212A1 (en) * | 2019-11-26 | 2022-06-09 | Lycored Ltd. | Cannabinoid and lycopene anti-inflammatory synergistic combinations |
| CN115605289A (zh) * | 2020-04-29 | 2023-01-13 | 利加尔有限合伙公司（Nz） | 印迹聚合物及其使用方法 |
| CA3152633A1 (en) * | 2020-07-27 | 2022-02-03 | Canopy Growth Corporation | Methods of synthesizing cannabielsoin and analogs thereof |
| WO2022165165A1 (en) * | 2021-01-29 | 2022-08-04 | The Johns Hopkins University | Limonene effects on tetrahydrocannabinol (thc)-induced anxiety |
| CN113368086B (zh) * | 2021-08-11 | 2021-12-03 | 龙麻(上海)医药研发有限责任公司 | 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用 |
| WO2023245185A1 (en) * | 2022-06-17 | 2023-12-21 | New Growth Brands, Inc. | Compositions comprising cannabinoids and methods of preparation and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009019322A1 (de) * | 2009-04-30 | 2010-11-11 | The Health Concept Gmbh | Verfahren zur Herstellung von Synthetischen Cannabinoiden |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) * | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| CA2931039C (en) * | 2013-11-20 | 2022-07-12 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| WO2016138505A1 (en) * | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
-
2018
- 2018-03-01 PE PE2019001790A patent/PE20200383A1/es unknown
- 2018-03-01 CN CN201880028815.7A patent/CN110582206A/zh active Pending
- 2018-03-01 EP EP18760302.2A patent/EP3589129A4/en not_active Withdrawn
- 2018-03-01 AU AU2018227544A patent/AU2018227544A1/en not_active Abandoned
- 2018-03-01 WO PCT/US2018/020440 patent/WO2018160827A1/en unknown
- 2018-03-01 BR BR112019018088-5A patent/BR112019018088A2/pt not_active Application Discontinuation
- 2018-03-01 CA CA3054690A patent/CA3054690A1/en active Pending
- 2018-03-01 MX MX2019010370A patent/MX2019010370A/es unknown
-
2019
- 2019-08-26 IL IL26892919A patent/IL268929A/en unknown
- 2019-08-29 CO CONC2019/0009413A patent/CO2019009413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018227544A1 (en) | 2019-08-29 |
| IL268929A (en) | 2019-10-31 |
| WO2018160827A1 (en) | 2018-09-07 |
| BR112019018088A2 (pt) | 2020-03-24 |
| MX2019010370A (es) | 2019-10-22 |
| EP3589129A1 (en) | 2020-01-08 |
| PE20200383A1 (es) | 2020-02-24 |
| EP3589129A4 (en) | 2020-11-25 |
| CA3054690A1 (en) | 2018-09-07 |
| CN110582206A (zh) | 2019-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019009413A2 (es) | Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados | |
| BR112017018276A2 (pt) | ?composição que compreende peptidase e biotensoativo e seu uso? | |
| CY1122076T1 (el) | Φυτικα εκχυλισματα που περιεχουν κανναβινοειδες σαν νευρο-προστατευτικοι παραγοντες | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| CL2019001187A1 (es) | Combinaciones fungicidas. | |
| CO2021005884A2 (es) | Moduladores de la alfa-1 antitripsina | |
| MX2017010872A (es) | Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales. | |
| AR112015A1 (es) | Composiciones sólidas para administración oral | |
| CL2018000070A1 (es) | Modulares de diaciglicerol aciltransderasa 2 (dgta2) | |
| CL2019001249A1 (es) | Composiciones de recubrimiento y métodos de uso de las mismas. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| AR113419A1 (es) | Formulación aerosolizable | |
| UY38284A (es) | Composiciones y métodos para agonizar el receptor cb2 | |
| ECSP19072372A (es) | Moduladores de la expresión de pcsk9 | |
| CL2016003023A1 (es) | “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct | |
| CO2020001325A2 (es) | Combinaciones herbicidas sinérgicas | |
| UY37342A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| SE1651620A1 (sv) | A field emission light source adapted to emit UV light | |
| AR073057A1 (es) | Combinaciones insecticidas de abamectina y ciflumetofeno y composiciones que las comprenden. | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| NI201900006A (es) | Combinaciãn de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacãuticas de ãstos | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| MX2020001992A (es) | Peliculas acrilicas quebradizas y etiquetas para la prevencion de la falsificacion que comprenden las mismas. | |
| MX2020010424A (es) | Comprimido o composicion que contiene n-acil etanolamina y cannabinoides. |